DCM
MRTX

Driehaus Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Driehaus Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,000
Closed -$247K – 459
2022
Q1 		$247K Sell
3,000
-180,446
-98% -$18.5M ﹤0.01% 368
2021
Q4 		$26.9M Buy
183,446
+34,619
+23% +$5.37M 0.27% 114
2021
Q3 		$26.3M Buy
148,827
+85,736
+136% +$13.8M 0.31% 95
2021
Q2 		$10.2M Sell
63,091
-28,890
-31% -$4.64M 0.14% 218
2021
Q1 		$15.8M Sell
91,981
-10,836
-11% -$2.15M 0.23% 136
2020
Q4 		$22.6M Sell
102,817
-5,449
-5% -$1.18M 0.36% 87
2020
Q3 		$18M Buy
108,266
+5,158
+5% +$706K 0.37% 78
2020
Q2 		$11.8M Buy
103,108
+1,353
+1% +$131K 0.29% 112
2020
Q1 		$7.82M Sell
101,755
-3,550
-3% -$318K 0.26% 101
2019
Q4 		$13.6M Sell
105,305
-86,712
-45% -$8.36M 0.36% 78
2019
Q3 		$15M Sell
192,017
-85,379
-31% -$8.01M 0.49% 52
2019
Q2 		$28.6M Buy
277,396
+83,645
+43% +$6.51M 0.9% 19
2019
Q1 		$14.2M Sell
193,751
-35,024
-15% -$2.38M 0.53% 51
2018
Q4 		$9.71M Sell
228,775
-161,202
-41% -$6.42M 0.42% 66
2018
Q3 		$18.4M Sell
389,977
-51,493
-12% -$2.87M 0.57% 37
2018
Q2 		$21.8M Buy
+441,470
New +$16.7M 0.74% 18
2016
Q2 		– Sell
-125,178
Closed -$2.68M – 669
2016
Q1 		$2.68M Sell
125,178
-51,295
-29% -$1.15M 0.09% 233
2015
Q4 		$5.58M Buy
176,473
+25,661
+17% +$906K 0.19% 120
2015
Q3 		$5.19M Buy
150,812
+20,766
+16% +$628K 0.19% 129
2015
Q2 		$4.09M Buy
130,046
+38,104
+41% +$1.12M 0.14% 177
2015
Q1 		$2.7M Sell
91,942
-490
-0.5% -$11.5K 0.09% 271
2014
Q4 		$1.71M Buy
92,432
+2,244
+2% +$37.8K 0.07% 338
2014
Q3 		$1.58M Sell
90,188
-73,487
-45% -$1.37M 0.06% 369
2014
Q2 		$3.27M Sell
163,675
-74,355
-31% -$1.44M 0.11% 258
2014
Q1 		$4.54M Buy
+238,030
New +$4.95M 0.14% 183

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Driehaus Capital Management's MRTX Position: Q2 2022 in Review

Driehaus Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 3,000 shares — an estimated $247K sold.

Driehaus Capital Management first reported a position in MRTX in Q1 2014 and held it in 25 quarters. The position peaked at $28.6M in Q2 2019. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

  • Driehaus Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Driehaus Capital Management sold 3,000 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $247K.
  • Driehaus Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 25 quarters.
  • Driehaus Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $28.6M in Q2 2019.
  • 230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Driehaus Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.